Clinical Trial

A Cohort Study on Treating Primary Nocturnal Enuresis by Regulating Central-Peripheral Circadian Rhythm

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Primary nocturnal enuresis (PNE), a prevalent pediatric disorder, suffers from therapeutic limitations characterized by low efficacy and high relapse rates. Targeting its core pathophysiology could significantly improve treatment outcomes. Growing evidence implicates circadian dysregulation in PNE pathogenesis. Our preliminary fMRI cohort identified abnormal functional connectivity between the suprachiasmatic nucleus (SCN, the central circadian pacemaker) and superior temporal gyrus in PNE patients, with clinical data confirming circadian realignment correlates with symptom remission. Small-scale pilot studies and clinical observations indicate that modulating central and peripheral circadian rhythms significantly alleviates PNE symptoms. This study will establish a circadian-focused PNE cohort to quantify therapeutic efficacy and elucidate underlying mechanisms, ultimately driving the development of mechanism-based therapies for PNE.
Trial Details
NCT Number NCT07003126
Lead Sponsor Shanghai Children's Medical Center
Conditions Primary Nocturnal Enuresis
Enrollment 200 participants
Start Date 2025-07-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-04